Tempo Therapeutics secured $12m in a Series A financing round led by Galaxy Sirius Partners and Johnson & Johnson Innovation – JJDC to advance its synthetic tissue scaffold products into clinical trials.

Mar 20, 2024•over 1 year ago

Amount Raised

$12 Million

Round Type

series a

San DiegoBiotechnology

Investors

Johnson & Johnson Innovation – JjdcGalaxy Sirius Partners

Description

Tempo Therapeutics has closed a $12 million Series A funding round led by Galaxy Sirius Partners and Johnson & Johnson Innovation – JJDC. The funding will enable the company to advance its synthetic tissue scaffold products, TT101 and TT108, into clinical trials and further develop its microporous-annealed-particle (MAP) technology platform for regenerative medicine.

Company Information

Company

Tempo Therapeutics

Location

3030 BUNKER HILL STREET

San Diego, California, United States

About

Tempo Therapeutics, headquartered in San Diego, California, is pioneering a new era in tissue engineering biotechnology, using our proprietary MAP material science technology. Using MAP technology, Tempo is building functional tissue and organs within patients, in real time, to treat disease, and developing next-generation vaccine technologies that are shelf stable, stockpile-able, and protect against multiple diseases with a single injection. Our mission is to use MAP material technology to enable the future of medicine.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends